The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

NCT04860700 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Malignant Adrenal Gland Pheochromocytoma
Malignant Paraganglioma
Pheochromocytoma, Metastatic
Paraganglioma, Malignant
Paraganglioma, Extra-Adrenal

Interventions

DRUG: anlotinib hydrochloride

Sponsor

Peking Union Medical College Hospital